Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study

Debra C. ten Brink1*, Rowan Martin-Hughes1, Mark E. Minnery1, Aaron J. Osborne1, Heather-Marie A. Schmidt2,3, Shona Dalal3, Kimberly E. Green4, Reshmie Ramaurtarsing5, David P. Wilson1,6,7, Sherrie L. Kelly1

1 Burnet Institute, Melbourne, Victoria, Australia, 2 United Nations Programme on HIV/AIDS, Regional Office for Asia and the Pacific, Bangkok, Thailand, 3 World Health Organization, Geneva, Switzerland, 4 PATH, Hanoi, Vietnam, 5 Institute of HIV Research and Innovation, Bangkok, Thailand, 6 Monash University, Melbourne, Victoria, Australia, 7 Bill and Melinda Gates Foundation, Seattle, Washington, United States of America

* debra.tenbrink@burnet.edu.au

Abstract

Introduction

More than 70% of new HIV infections in Asia occurred in eight countries in 2020: Cambodia, China, India, Indonesia, Myanmar, Nepal, Thailand, and Vietnam—with a rising incidence among men who have sex with men (MSM). The World Health Organization (WHO) recommends pre-exposure prophylaxis (PrEP) for those at risk of acquiring HIV, yet wide-scale implementation of PrEP, on a daily or event-driven basis, has been limited in Asia.

Methods

The Optima HIV model was applied to examine the impact of scaling-up PrEP over five-years to cover an additional 15% of MSM compared with baseline coverage, a target deemed feasible by regional experts. Based on behavioral survey data, we assume that covering 15% of higher-risk MSM will cover 30% of all sexual acts in this group. Scenarios to compare the impact of generic-brand daily dosing of PrEP with generic event-driven dosing (15 days a month) were modelled from the start of 2022 to the end of 2026. Cost-effectiveness of generic versus branded PrEP was also assessed for China, the only country with an active patent for branded, higher cost PrEP. The impact on new HIV infections among the entire population and cost per HIV-related disability-adjusted life year (DALY) averted were estimated from the beginning of 2022 to the end of 2031 and from 2022 to 2051.

Results

If PrEP were scaled-up to cover an additional 15% of MSM engaging in higher-risk behavior from the beginning of 2022 to the end of 2026 in the eight Asian countries considered, an additional 100,000 (66,000–130,000) HIV infections (17%) and 300,000 (198,000–390,000)
HIV-related DALYs (3%) could be averted over the 2022 to 2031 period. The estimated cost per HIV-related DALY averted from 2022 to 2031 ranged from US$600 for event-driven generic PrEP in Indonesia to US$34,400 for daily branded PrEP in Thailand. Over a longer timeframe from 2022 to 2051, the cost per HIV-related DALY averted could be reduced to US$100–US$12,700.

Conclusion

PrEP is a critical tool to further reduce HIV incidence in highly concentrated epidemics. Implementing PrEP in Asia may be cost-effective in settings with increasing HIV prevalence among MSM and if PrEP drug costs can be reduced, PrEP could be more cost-effective over longer timeframes.

Introduction

The use of pre-exposure antiretroviral drugs as an additional option to prevent HIV acquisition has been recommended by the World Health Organization (WHO) for those at “substantial risk” of HIV infection, referring to populations where HIV incidence is greater than three per 100 person-years of life [1].

In 2020, 16% of all new HIV infections worldwide were estimated to have occurred in Asia [2]. Together, Cambodia, China, India, Indonesia, Myanmar, Nepal, Thailand, and Vietnam accounted for an estimated 70% of all new HIV infections in Asia in 2020 [2–4]. These infections were predominantly concentrated among key populations, with the UNAIDS Global 2021 Report outlining a concerning increase among men who have sex with men (MSM) [2, 5]. MSM accounted for almost 53% of new HIV infections in Asia among 15- to 49-year-olds in 2020 [2]. As condom use remains low in this population, other prevention mechanisms such as PrEP may provide a more accessible prevention option for MSM. Other regions with notable HIV incidence among MSM, such as Australia, Europe, and the United States, have shown significant reductions in new HIV infections associated with PrEP [6].

Amongst the eight countries in Asia, only Thailand and Vietnam have thus far rolled out large-scale PrEP programs for key populations [5]. In 2016, Thailand offered PrEP for MSM and transgender women, the first country in the region to do so [7], with Vietnam following suit in 2017 [8]. Cambodia began a phased approach to national rollout of PrEP in 2019 [9]. China, India, Myanmar, and Nepal have implemented PrEP on a demonstrative basis from 2019 onwards [2], with a multicenter trial ongoing in China since 2018 [10]. Estimates from AIDS Vaccine Advocacy Coalition data (AVAC) PrEPWatch indicate that among these eight countries, Thailand has the largest number of people on PrEP, with an estimated 41,000 current users as of 27 January 2022, an estimated number of 29,000 in Vietnam, 4,500 in China, 3,000 in Nepal, and 1,500 in India [11]. The estimates for Cambodia, Indonesia, and Myanmar were less than 500 (UNAIDS and WHO communication), suggesting a limited number of PrEP users to date.

The most widely implemented PrEP drug regimens are a daily pill in an oral combination of tenofovir disoproxil fumarate (TDF) (300mg) with emtricitabine (FTC) (200mg) or lamivudine (3TC) (300mg) tablets [12, 13]. In 2019, WHO recommended an additional option to the daily PrEP regimen, namely event-driven or “2+1+1” dosing for PrEP [14]. Findings from ongoing studies in France and Canada report that event-driven dosing, two tablets 2 to 24
hours before, followed by one tablet 24 hours after and another 48 hours after a single high-risk event (e.g., condomless anal sex), prevent HIV infections to the same degree as daily PrEP for MSM [15].

High drug costs for generic as well as branded PrEP, have been cited as a key determinant for the cost-effectiveness of PrEP [16–21]. Encouragingly, prices have decreased markedly over the last few years with increasing numbers of pre-qualified generic versions of TDF/FTC entering the market, providing an opportunity for countries to acquire PrEP at much lower cost [22]. Nevertheless, existing literature finds that PrEP may be limited in its cost-effectiveness, but may be more cost-effective when targeting populations with higher incidence of HIV. A modelling study examining the impact of PrEP in a theoretical hyperendemic setting determined that a delivery cost of PrEP of US$250 per person per year was too high for implementation and scale-up to be cost-effective, thus limiting any added potential for reduction in HIV incidence in this setting due to PrEP cost [23]. In urban settings in Vietnam, daily PrEP was found to be cost-effective while event-driven PrEP was found to be cost-saving, should PrEP coverage reach 60% by 2050 among all key populations—MSM, people who inject drugs and female sex workers and their partners [24]. In Thailand, Suraratdecha and colleagues showed that providing PrEP at US$222 per person per year could be cost-effective, with an estimated ICER of US$4,836 per HIV-related disability-adjusted life year (DALY) averted when targeted at high-risk MSM or US$7,089 when targeted at all MSM over a five year period from 2017 to 2022 [17]. Without defining a cost-effectiveness threshold, the following modelling studies reported their incremental cost-effectiveness ratios (ICER). A modelling study examining PrEP implementation targeted at high-risk MSM in China estimated that PrEP could cost approximately US$24,000-US$26,000 per quality-adjusted life year gained [25]. Implementing daily PrEP coupled with twice yearly HIV testing in India was modelled to have an ICER of US$1,000 per year of life saved [26].

Considering the relatively low uptake of PrEP in Asia to date, we modelled the potential impact and cost-effectiveness of PrEP implementation and scale-up for daily as well as event-driven dosing for eight countries in Asia. To our knowledge, this is the first paper to estimate the impact and cost-effectiveness of daily versus event-driven dosing of PrEP for the entire region, including comparison of branded with generic PrEP in China.

**Methods**

**Model design**

This analysis was carried out using Optima HIV (v2.10.1, hiv.optimamodel.com), a population-based compartmental model [27]. Demographic, epidemiological, and behavioral estimates and data were used to inform HIV transmission among context-specific populations. Existing models for Cambodia, China, India, Indonesia, Myanmar, Nepal, Thailand, and Vietnam [28] were updated with most recent estimates for population size and HIV prevalence (S1 Table), as well as for expenditure and coverage for HIV prevention, testing, and treatment from 2010 to 2020.

**Scenario analysis**

This analysis follows principles from the International Decision Support Initiative (iDSI) reference case for conducting cost-effectiveness studies [29]. To allow for consistent comparison of scenario conditions to baseline, baseline coverage of PrEP usage (% of MSM) according to AVAC was applied as of 27 January 2022: Cambodia (<500, 0%), China (4,500, 0%), India (1,500, 0%), Indonesia (<500, 0%), Myanmar (<500, 0%), Nepal (3,000, 5%), Thailand (41,000, 8%), and Vietnam (29,000, 15%) [11]. It is assumed that all existing PrEP users were
MSM, though it is possible that not all users are MSM and that not all estimated users are captured in these estimates. We examined two scenarios using generic drug costs with either daily PrEP (one pill a day) or event-driven dosing (an average of 15 pills per month following the study by Molina and colleagues [30]). As a patent for branded PrEP is still in effect in China, the impact on cost-effectiveness using generic and branded TDF/FTC PrEP unit costs was examined. Latest reported HIV testing rates and antiretroviral treatment (ART) coverage as of 2021 were held constant to the end of 2026. Impact was measured through estimating the number new HIV infections and HIV-related DALYs in both the baseline and scale-up of PrEP scenarios for the entire population, as some MSM may have condomless vaginal or anal sex with cis-gender females.

**Target population.** This analysis was limited to PrEP implementation among MSM. Due to limitations in data availability across all countries, potential implementation of PrEP for transgender people was excluded. Efficacy of PrEP to prevent HIV transmission was assumed to be 82% for both daily and event-driven PrEP in the model. Efficacy has been estimated at ~99% in clinical trials [1, 30–32], the 82% efficacy value applied in this analysis corrects for lower adherence. We considered a scenario in which PrEP was implemented or scaled-up over a five-year period from the beginning of 2022 to reach coverage levels of an additional 15% of MSM by the end of 2026 compared with baseline levels, a coverage level deemed feasible by consensus of PrEP experts reached at a meeting on ‘Estimating the Cost-Effectiveness and Impact of PrEP’ held 9–10 December 2019 in Bangkok, Thailand. Within the MSM population, there are varying degrees of HIV risk. It is assumed that those engaging in the highest risk events, such as multiple sexual partners with which they engage in condomless anal sex, are also the most likely to opt-in to use PrEP as they understand their own risk profile [33]. Based on behavioural surveys with MSM in Cambodia it was estimated that 30% of MSM and transgender population accounted for 75% of higher risk acts [34]. This analysis more cautiously assumes that for all countries included, covering 15% of the highest-risk MSM will cover 30% of all commercial, regular and/or casual sexual acts among MSM. In countries with <500 of MSM currently covered by PrEP, this will mean 30% of acts among the MSM population are covered. In countries with a higher baseline coverage of PrEP such as the almost 15% of MSM currently covered in Vietnam, this may mean 60% coverage of all acts among MSM.

**Study timeframe**

The timeframe for this analysis assumes new implementation or scale-up of PrEP, depending on baseline coverage, at the beginning of 2022. It assumes 15% of high-risk MSM are covered by PrEP, in addition to the baseline coverage. PrEP can be taken either with daily or event-driven dosing for five years, by the end of 2026, and coverage is assumed to stay constant thereafter. The epidemiological impact is measured by estimating HIV incidence and HIV-related DALYs from the beginning of 2022 to the end of 2031. A ten- and thirty-year timeframe are applied for impact, as it is expected that the epidemiological impact will be limited over the 5-year implementation period.

**PrEP unit costs**

Costs to deliver PrEP (Table 1) to one person for one year (i.e., unit cost) for each country were derived from previous country modelling studies [17, 18, 35, 36], the WHO Global Price Report Mechanism [37], and the WHO-CHOICE project [38], and informed by expert communication with co-authors H-MS [UNAIDS], SD [WHO], and respective country partners. PrEP cost components include one HIV test session prior to PrEP initiation, antiretroviral drugs (generic TDF/FTC or TDF/3TC), health personnel time to deliver services, quarterly
HIV testing, and biannual testing for sexually transmitted infections (chlamydia, syphilis, and gonorrhoea) (additional details provided in S2 Table). It is assumed that those at highest risk for acquiring HIV are identified and tested through the same mechanisms as those at lower risk. Though suggested by WHO guidelines, creatinine and hepatitis B testing were not included in these costs due to lack of data. Additionally, demand generation and effective PrEP education and promotion costs were not included due to limited data availability around the necessity of demand generation. Similarly, there was no differentiation of delivery modalities for PrEP.

PrEP drug prices can differ substantially depending on approval and availability of generic versus branded PrEP. Communication with country partners indicated that generic PrEP is not yet registered in China, but available on the public market. The unit costs shared by the same country partners revealed that the unit cost for branded PrEP was twice as high as the unit cost for generic PrEP. As the patent is still in effect for branded PrEP in China, a cost-effectiveness analysis was conducted to compare generic and branded TDF/FTC PrEP unit costs [18]. It is uncertain as to what drives the cost of both the generic and branded PrEP in China.

Cost per HIV-related DALY averted

To evaluate the cost-effectiveness of implementing PrEP, costs per HIV-related DALY averted were estimated for each country from 2022 to 2031, as well as the longer term 2022 to 2051. Disability weights to inform HIV-related DALYs were applied from the Global Burden of Disease study [42]. HIV-related DALYs were discounted at an annual rate of 3% until the end of 2026. ART costs saved over the 50-year period (estimated life expectancy of a PrEP user), as a result of potential new HIV infections averted through PrEP implementation, were calculated and discounted at 3% [43]. HIV-related DALYs calculated until 2031 and 2051 we also discounted at 3%. ART unit costs used to calculate the potential ART treatment costs that could be averted through PrEP administration are listed in S3 Table.

Sensitivity analysis

A lower bound of an additional 10% and an upper bound of an additional 20% PrEP coverage, around the target of baseline + 15% coverage, was modelled from the beginning of 2022 to the end of 2026 to assess the impact of varying coverage levels on cost-effectiveness. To account

Table 1. PrEP unit costs.

| Country                        | Average estimated PrEP unit cost (USD) | Daily Branded | Daily Generic | Event-driven* |
|-------------------------------|----------------------------------------|---------------|---------------|---------------|
| Cambodia [35, 36, 38]         | NA                                     | $75           | NA            | $55           |
| China [communication with country partners through HM-S] | $1,814                                 | $884          | $962          | $504          |
| India [36–38]                 | NA                                     | $113          | NA            | $78           |
| Indonesia [36, 38, 39]        | NA                                     | $321          | NA            | $190          |
| Myanmar [37, 38]              | NA                                     | $118          | NA            | $89           |
| Nepal [36–38, 40]             | NA                                     | $128          | NA            | $93           |
| Thailand [17, 37]             | NA                                     | $252          | NA            | $141          |
| Vietnam [36–38, 41]           | NA                                     | $157          | NA            | $112          |

*15 doses per month [30]

https://doi.org/10.1371/journal.pone.0268240.t001
for uncertainty relating to unit costs of PrEP, a 90% lower and a 110% upper bound for PrEP costs was also modelled.

**Results**

If PrEP were implemented or scaled-up in 2022 in the eight Asian countries considered in this study, with an additional 15% coverage of MSM achieved by the end of 2026, an additional 100,000 (66,000–130,000) HIV infections (17%) and 300,000 (198,000–390,000) HIV-related DALYs (3%) could be averted over the 2022 to 2031 period compared with baseline PrEP coverage (Table 2). In addition to DALYs averted, this could result in cumulative saving of almost US$12.3 million in ART costs in all Asian countries considered.

**Cost per HIV-related DALY averted**

The resulting cost per HIV-related DALY averted for all scenarios are listed in Table 3. The cost per HIV-related DALYs averted was estimated to be the lowest in Indonesia, at US$600 for event-driven generic PrEP dosing at 15 days per month, if an additional 15% coverage of MSM were to be achieved by the end of 2026. This is primarily due to savings from the reduction in the unit cost and frequency of event-driven dosing of antiretrovirals (ARVs) compared with a daily regimen, as well as the estimated increasing HIV epidemic among MSM by the end of 2026. Thailand is estimated to have the highest cost per HIV-related DALY averted.

### Table 2. Estimated additional new HIV infections and HIV-related DALYs averted by 2031 through PrEP coverage of 15% of MSM from 2022 to 2026 (range of 10% to 20% PrEP coverage).

| Country | Additional new HIV infections averted | Percent of total HIV infections averted | Additional HIV-related DALYs averted | Percent of total HIV-related DALYs averted |
|---------|--------------------------------------|----------------------------------------|-------------------------------------|------------------------------------------|
| Cambodia | 700 (500–900) | 28% (20%-36%) | 460 (300–600) | 11% (8%-13%) |
| China   | 36,000 (24,300–47,400) | 19% (13%-26%) | 122,000 (82,000–160,300) | 4% (3%-5%) |
| India   | 6,400 (4,300–8,500) | 19% (13%-26%) | 12,600 (8,500–16,600) | 2% (2%-3%) |
| Indonesia | 51,500 (34,300–68,800) | 15% (10%-19%) | 152,000 (101,700–202,800) | 3% (2%-4%) |
| Myanmar | 1,000 (700–1,400) | 18% (12%-24%) | 2,500 (1,700–3,300) | 2% (1%-3%) |
| Nepal   | 1,000 (700–1,400) | 20% (13%-26%) | 3,100 (2,100–4,100) | 4% (3%-5%) |
| Thailand| 1,200 (800–1,500) | 24% (16%-31%) | 1,800 (1,200–2,500) | 1% (1%-2%) |
| Vietnam | 1,200 (900–1,600) | 31% (21%-41%) | 1,000 (700–1,300) | 4% (3%-5%) |

https://doi.org/10.1371/journal.pone.0268240.t002

### Table 3. Estimated cost per HIV-related DALY averted by 2031* (USD).

| Country | Daily generic | Event-driven generic |
|---------|---------------|----------------------|
| Cambodia | $5,500 ($4,600—$10,000) | $4,000 ($3,300—$4,600) |
| China   | $15,600 ($13,800—$17,400) | $8,900 ($7,800—$9,900) |
| India   | $18,100 ($16,000—$20,100) | $12,600 ($11,200—$14,100) |
| Indonesia | $1,000 ($900—$1,100) | $600 ($500—$700) |
| Myanmar | $5,300 ($4,700—$5,900) | $3,900 ($3,500—$4,400) |
| Nepal   | $3,300 ($2,900—$3,600) | $2,400 ($2,100—$2,600) |
| Thailand| $34,400 ($30,300—$38,600) | $18,800 ($16,600—$21,100) |
| Vietnam | $15,400 ($13,200—$17,800) | $10,700 ($9,200—$12,300) |

* Assuming baseline + 15% coverage of MSM is achieved by end of 2026 and factoring savings from ART costs averted in this timeframe and 3% discounting of costs and DALYs. Ranges defined as (10% MSM coverage and 110% PrEP unit cost) to (20% MSM coverage and 90% PrEP unit cost).

https://doi.org/10.1371/journal.pone.0268240.t003
while Indonesia is estimated to have the lowest cost per DALY averted. In China, event-driven generic PrEP could be more cost-effective than daily branded PrEP (Table 4).

To estimate the cost-effectiveness of the implementation or scale-up of PrEP in the longer term, Table 5 illustrates the cost per HIV-related DALY averted by 2051 if PrEP could reach an additional coverage of 15% of MSM in 5 years from 2022 to the end of 2026. Compared with the 2022 to 2031 period, the extra 20 years could result in a substantial reduction in the cost per HIV-related DALY. In the event-driven scenario, the cost per HIV-related DALY averted could be reduced from US$12,600 to US$4,700 (an almost 70% reduction) in India, ranging towards US$4,000 to US$400 (a 90% reduction) in Cambodia.

**Discussion**

PrEP implementation and scale-up among MSM could have a substantial public health impact in eight countries which account for over 70% of new HIV infections in Asia. If PrEP were implemented and scaled-up in 2022 in the eight Asian countries considered in this study, with an additional 15% coverage of MSM achieved by the end of 2026, an additional 100,000 (66,000–130,000) HIV infections (17%) and 300,000 (198,000–390,000) HIV-related DALYs (3%) could be averted over the 2022 to 2031 period compared with baseline PrEP coverage. In addition to HIV infections and DALYs averted, this could result in cumulative saving of almost US$12.3 million in ART costs over the five-year timeframe for these countries. Based on historical trends from 2000 onwards in the Optima HIV calibrations, it is estimated that HIV prevalence could increase among MSM in Cambodia, China, Indonesia, and Vietnam, but could decrease in India, Myanmar, and Thailand, while plateauing in Nepal, if previous trends are projected into the future. The estimates for costs per HIV-related DALY averted

---

Table 4. Estimated cost per HIV-related DALY averted by 2031* (USD) for generic and branded PrEP in China.

| Country | Daily branded | Daily Generic | Event-driven branded | Event-driven generic |
|---------|---------------|---------------|----------------------|----------------------|
| China   | $32,000 ($29,300—$34,700) | $15,600 ($14,200—$16,800) | $16,900 ($15,500—$18,400) | $8,900 ($8,100—$9,600) |

*Assuming baseline + 15% coverage of MSM is achieved by end of 2026 and factoring savings from ART costs averted in this timeframe and 3% discounting of costs and DALYs. Ranges defined as (10% MSM coverage and 90% PrEP unit cost) to (20% MSM coverage and 110% PrEP unit cost).

https://doi.org/10.1371/journal.pone.0268240.t004

Table 5. Estimated cost per HIV-related DALY averted by 2051* (USD).

| Country | Daily generic | Event-driven generic |
|---------|---------------|----------------------|
| Cambodia | $700 ($540—$770) | $400 ($270—$440) |
| China   | $2,500 ($2,200—$2,800) | $1,400 ($1,200—$1,500) |
| India   | $6,900 ($6,000—$7,700) | $4,700 ($4,200—$5,300) |
| Indonesia | $100 ($90—$110) | $100 ($90—$110) |
| Myanmar | $1,000 ($900—$1,100) | $700 ($630—$770) |
| Nepal   | $500 ($450—$660) | $300 ($270—$440) |
| Thailand | $12,700 ($11,200—$14,300) | $6,100 ($5,400—$6,900) |
| Vietnam | $5,200 ($4,400—$6,200) | $3,100 ($2,600—$3,700) |

*Assuming baseline + 15% coverage of MSM is achieved by end of 2026 and factoring savings from ART costs averted in this timeframe and 3% discounting of costs and DALYs. Ranges defined as (10% MSM coverage and 90% PrEP unit cost) to (20% MSM coverage and 110% PrEP unit cost).

https://doi.org/10.1371/journal.pone.0268240.t005
generally follow these trends (S2 Table). In Thailand and Vietnam, the number of new HIV infections among the entire population is projected to decrease significantly, while there is a high baseline coverage of MSM of PrEP, resulting in a higher cost per DALY averted.

Estimated costs per HIV-related DALY averted vary greatly between countries over the 2022 to 2031 period. Our results show higher costs per HIV-related DALY averted in the daily dosage scenarios compared with other studies in China [18]. However, these studies assumed higher efficacy, closer to 100%, than our assumption of 82% efficacy, which accounts for less than complete adherence. The 2022 to 2051 timeframe, however, illustrates significant reductions of 70% to 90% in the cost per HIV-related DALY averted, demonstrating the progressive cost-effectiveness of PrEP scale-up over the longer term.

The global community has yet to agree on what cost-effectiveness threshold (CET) should be applied when assessing the cost-effectiveness of an intervention [44]. Previously identified WHO-CHOICE estimates for CETs at 1–3 x GDP per capita were deemed too easily attainable in constrained low- and middle-income settings, disregarding the opportunity cost of investment in an expensive intervention for overall health [45]. The need for supply side considerations, the opportunity cost of changes in healthcare expenditure, alongside demand side considerations, the estimated social value of what an intervention ought to cost, should therefore be considered. The opportunity cost, or supply side CET, can be approximated as 0.5 x GDP per capita [46, 47]. When applying this threshold using 2020 World Bank GDP per capita estimates [48], PrEP was only demonstrated to be cost-effective in Indonesia in both the daily ($1,000 per HIV-related DALY averted by 2031) and event-driven scenarios ($600 per HIV related DALY averted by 2031) at a CET of $1,900. If the longer-term analysis to 2051 for both daily event-driven PrEP is considered with the same CET, Cambodia, China, Indonesia, Nepal are deemed cost-effective, while India, Myanmar, Thailand, and Vietnam are not. Countries in which daily and event-driven PrEP was found to be a cost-effective intervention, have increasing HIV prevalence in Optima HIV models for MSM, suggesting PrEP may be most cost-effective in settings with growing prevalence.

ARV drug costs for PrEP account for 50% to 98% of the unit costs for all countries considered, illustrating the need for countries to be able to access lower-cost PrEP. Our results show significant variation in annual drug costs for PrEP (US$38–US$1,680) across the eight countries considered. If the region could acquire PrEP drugs at the lowest cost reported in this analysis, namely US$3–4 for a bottle of 30 pills, this would greatly improve the affordability of PrEP. The comparison of daily versus event-driven PrEP use in this analysis allows for insights into the potential increased impact on cost-effectiveness. Willingness-to-pay by national governments and the ability of consumers to cover out-of-pocket expenses [49] will be a major factor in determining the feasibility of implementing and scaling PrEP, especially in countries where only branded PrEP is commonly available [50]. Nevertheless, offering event-driven PrEP as an option for MSM, in addition to daily dosing could potentially be more cost-effective, based on the results of event-driven PrEP alone. It remains critical to offer both dosing options to all potential and current PrEP users, so they may choose the method that best fits their needs.

It is unclear how the COVID-19 pandemic has influenced access to PrEP in Asia; however, recent reports suggest moderate disruption mainly due to limitations of informal access because of mobility restrictions. As an example, in Thailand there have been efforts to remedy formal access issues through telehealth consultations, laboratory sample collections at home, home delivery of drugs, and disbursement of longer supply of medication per prescription [51]. These adaptations may lower barriers to initiate and adhere to PrEP for those who require it.

Study limitations include data availability and the necessity for certain assumptions to be used. Up-to-date estimates of MSM population size and HIV prevalence were not available (S1
Table). National estimates of MSM population size and HIV prevalence may also be underestimated due to stigmatization or insufficient reporting methods [52, 53] potentially resulting in an underestimation of the potential impact of PrEP. Evidence-informed assumptions needed to be made surrounding PrEP drug costs, acceptability, condomless sex surrounding PrEP use, and efficacy, including adherence to daily or event-driven dosing regimens. Efficacy was assumed to be 82% in this analysis, assuming a potentially unrealistic high adherence level of PrEP users. This analysis assumed either a daily or an event-driven scenario, though each country will have users in both scenarios, hence the actual cost per HIV-related DALY averted will lie somewhere in between the reported ranges. This analysis found higher cost per HIV-related DALY averted than other studies in the region, most likely due to this study’s conservative coverage target. If self-selection for PrEP use based on seasons of heightened risk-taking behaviour is more concentrated, as assumed in other settings [54], it may be that a higher coverage of casual acts could be achieved while PrEP may not be taken as frequently as assumed here, and PrEP cost-effectiveness would be higher as a result.

Since PrEP was introduced as part of the global HIV prevention package in 2015, its use has increased in the region [16]. However, it remains challenging to make assumptions around estimated baseline or future PrEP coverage and saturation levels, due to implementation of PrEP only being in the early stages in Asia. This study does not account for potential increased PrEP coverage through online or overseas acquisition of drugs, any medical costs to treat other sexually transmitted diseases, or additional costs for demand creation that may be necessary to increase coverage [55]. The impact and cost-effectiveness of rolling-out PrEP for people at substantial risk in other key populations and their partners needs further investigation. This includes levels of acceptability of and effective use of PrEP for additional people at substantial risk, including transgender people, sex workers, and people who inject drugs [56].

Cost-effectiveness will not be the only consideration when contemplating PrEP implementation and scale-up as reaching elimination targets may require delivery and availability of PrEP to reach those most in need, at any cost. COVID-19 has spurred further differentiation and simplification of PrEP service delivery in Asia—including offering PrEP through key population owned community clinics, distribution through primary health care, as well as through telehealth and mobile services [56, 57]. Due to enabling of refill collection and reduced stigma-related barriers, PrEP refills collected by peers or delivered by community health workers can facilitate increased demand for PrEP [7]. The addition of long-acting injectable (LAI) PrEP to the HIV prevention package could greatly optimize effective use of PrEP. Two recent LAI (cabotegravir) trials, HPTN 083 and HPTN 084, reported higher efficacy than standard oral PrEP [58, 59].

Conclusions
Scale-up of PrEP among MSM could avert 17% new HIV infections and 3% HIV-related DALYs in eight countries in Asia over the 2022 to 2031 period compared with baseline coverage of PrEP, potentially avert US$12.3 million in ART costs and may be cost-effective in settings with rising HIV prevalence among MSM. In addition, preventing rather than treating HIV could avert lifelong medical costs and disease burden. As with all newly implemented interventions, scale-up costs for PrEP may be higher initially, but marginal cost reductions are likely to be realized with increasing economies of scale, particularly if PrEP drug costs were to be reduced. The UNAIDS 2025 targets call for robust efforts to scale-up prevention activities, including PrEP, to ensure that 95% of people at risk of HIV infection have access to and use appropriate, prioritized, person-centered, and effective combination prevention options [60]. Supplementing the combination prevention package with PrEP may reach those at risk for
HIV for whom other preventative options are currently not appropriate, thereby potentially averting large numbers of HIV infections among MSM and their partners in Asia and substantially contributing to ending the HIV/AIDS epidemic.

Supporting information

S1 Table. Latest reported key epidemiological model inputs.
(DOCX)

S2 Table. PrEP unit cost breakdown.
(DOCX)

S3 Table. ART unit costs.
(DOCX)

Acknowledgments

The authors are grateful to national teams who collaborated on the HIV investment case studies that were supported by the World Bank Group. In addition, we would like to thank Wei Guo, Zhongdan Chen, and Jie Liu for sharing valuable data to inform our analyses.

Author Contributions

Conceptualization: Debra C. ten Brink, Shona Dalal, David P. Wilson, Sherrie L. Kelly.

Data curation: Debra C. ten Brink, Rowan Martin-Hughes, Mark E. Minnery, Aaron J. Osborne.

Formal analysis: Debra C. ten Brink.

Investigation: Debra C. ten Brink.

Methodology: Debra C. ten Brink, Rowan Martin-Hughes, Mark E. Minnery.

Software: Debra C. ten Brink, Rowan Martin-Hughes.

Supervision: Sherrie L. Kelly.

Writing – original draft: Debra C. ten Brink.

Writing – review & editing: Debra C. ten Brink, Rowan Martin-Hughes, Mark E. Minnery, Aaron J. Osborne, Heather-Marie A. Schmidt, Shona Dalal, Kimberly E. Green, Reshmie Ramaurtarsing, David P. Wilson, Sherrie L. Kelly.

References

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach Geneva: World Health Organization; 2016. [https://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1].

2. UNAIDS. UNAIDS Data 2021 Report. Geneva: UNAIDS; 2021. [https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf].

3. National AIDS Control Organisation I-NIoMS. India HIV Estimates 2019: Report. New Delhi; 2020. [http://naco.gov.in/sites/default/files/Estimation%20Report%202019.pdf].

4. National Health and Family Planning Commission of the People’s Republic of China. 2015 China AIDS Response Progress Report. 2015. [https://www.unaids.org/sites/default/files/country/documents/CHN_narrative_report_2015.pdf].

5. UNAIDS. UNAIDS Global 2020 Report. Geneva: UNAIDS; 2020. [https://aids2020.unaids.org/report].
6. UNAIDS. Miles to go: global AIDS update 2018. Geneva, Switzerland; 2018. [https://www.unaids.org/en/resources/documents/2018/global-aids-update].
7. Phanuphak N, Sungsing T, Jantarakapde J, Pengnonyang S, Trachunthong D, Mingkwanrungruang P, et al. Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand. Sex Health. 2018; 15(6):542–55. https://doi.org/10.1071/SH18065 PMID: 30249317
8. Vu BN, Nguyen NA. Scaling up PrEP through community leadership and public-private partnerships in Vietnam. AIDS 2018; Amsterdam, the Netherlands.
9. Ministry of Health NCIHA, Dermatology and STD,. Concept-note on HIV Pre-Exposure Prophylaxis (PrEP) Implementation in Cambodia. 2019. [https://niph.org.kh/niph/uploads/library/pdf/GL199_PrEP_concept_note-EN.pdf].
10. A multicenter, real-world study on two oral Truvada approaches to prevent HIV infection among MSM in China (CROPrEP) [press release].
11. AVAC. Global PrEP Watch February 2019 [https://www.prepwatch.org/resource/global-prep-tracker/].
12. Heneine W, Kashuba A. HIV prevention by oral preexposure prophylaxis. Cold Spring Harb Perspect Med. 2012; 2(3):a007419–a. https://doi.org/10.1101/cshperspect.a007419 PMID: 2293535
13. Appropriate Medicines: Options for Pre-Exposure Prophylaxis. Geneva: World Health Organization; 2018; [https://apps.who.int/iris/bitstream/handle/10665/273934/WHO-CDS-HIV-18.22-eng.pdf].
14. World Health Organization. What’s the 2+1+1? Geneva, Switzerland; 2019; [https://apps.who.int/iris/bitstream/handle/10665/325955/WHO-CDS-HIV-19.8-eng.pdf?ua=1].
15. Molina J-M, Ghosn J, Delaugerre C, Pialoux G, Kafiama C, Slama L, et al. Incidence of HIV-infection with daily or on demand oral PrEP with TDF/FTC in France. CROI.
16. Hoornenborg E, Krakower DS, Prins M, Mayer KH. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. AIDS 2018; 31(16):2179–91. https://doi.org/10.1097/QAD.0000000000001627 PMID: 29971734
17. Suraratdecha C, Stuart RM, Manopaboon C, Green D, Lertpiriyasuwat C, Wilson DP, et al. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand. J Int AIDS Soc. 2018; 21 Suppl 5:e25129–e. https://doi.org/10.1002/jia2.25129 PMID: 30033559
18. Zhang L, Peng P, Wu Y, Ma X, Soe NN, Huang X, et al. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China. AIDS Behav. 2019; 23(2):523–33. https://doi.org/10.1007/s10461-018-2205-3 PMID: 29971734
19. van de Vijver DAMC, Richter A-K, Boucher CAB, Gunsenheimer-Bartmeyer B, Kollan C, Nichols BE, et al. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. Euro Surveill. 2019; 24(7):1800398. https://doi.org/10.2807/1560-7917.ES.2019.24.7.1800398 PMID: 30782296
20. Durand-Zaleski I, Muton P, Chaneau I, Tremblay C, Rota C, Pialoux G, et al. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM. AIDS. 2018; 32(1):95–102. https://doi.org/10.1097/QAD.0000000000001658 PMID: 29210777
21. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hanksins C. The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies. PLOS Medicine. 2013; 10(3):e1001401. https://doi.org/10.1371/journal.pmed.1001401 PMID: 23554579
22. Médicins sans Frontières. Untangling The Web of Antiretroviral Price Reductions. Geneva, Switzerland; 2020. [https://msfaccess.org/sites/default/files/2020-11/HIV_Brief_Untangling-the-Web_2020.pdf].
23. Cremin I, Alsallaq R, Dybul M, Plot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013; 27(3):447–58. https://doi.org/10.1097/QAD.0b013e32833ca2dd PMID: 23296196
24. Gannon S, Herrick T, Green D, Green K, Thanh Nguyen H, Cummings R, et al. PrEP for key populations in Hanoi and Ho Chi Minh City, Vietnam has the potential to cost-effectively decrease HIV incidence in urban settings: a mathematical modeling analysis AIDS 20182018.
25. Li J, Peng L, Gilmore S, Gu J, Ruan Y, Zou H, et al. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China. BMC Infectious Diseases. 18(1):600. https://doi.org/10.1186/s12879-018-3516-8 PMID: 30486800
26. Kazemian P, Costantini S, Kumarasamy N, Pattiel AD, Mayer KH, Chandhiok N, et al. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. Clinical Infectious Diseases. 2019; 70(4):633–42.
27. Kerr CC, Stuart RM, Gray RT, Shattock AJ, Fraser N, Benedikt C, et al. Optima: a model for HIV epidemic prioritization, program prioritization, and resource optimization. Journal of Acquired Immune Deficiency Syndromes. 2015; 69(3):365–76. https://doi.org/10.1097/QAI.0000000000000605 PMID: 25803164

28. Kelly SL, Martin-Hughes R, Stuart RM, Yap XF, Kedziora DJ, Grantham KL, et al. The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS. Lancet HIV. 2018; 5(4): e190–e6. https://doi.org/10.1016/S2352-3018(18)30024-9 PMID: 29540265

29. Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns J, et al. The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value in Health. 2016; 19(8):921–8. https://doi.org/10.1016/j.jval.2016.04.015 PMID: 27978641

30. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015; 373(23):2237–46. https://doi.org/10.1056/NEJMoa1506273 PMID: 26624850

31. McCormack S, Dunn DT, Desai M, Dolling DJ, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England). 2016; 387(10013):53–60. https://doi.org/10.1016/S0140-6736(15)00056-2 PMID: 26364263

32. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4(151):151ra25. https://doi.org/10.1126/scitranslmed.3004006 PMID: 22972843

33. Luehring-Jones P, Palfai TP, Tahanyen KD, Maisto SA, Simons J. Pre-Exposure Prophylaxis (PrEP) Use is Associated With Health Risk Behaviors Among Moderate- and Heavy-Drinking MSM. AIDS Educ Prev. 2019; 31(5):452–62. https://doi.org/10.1521/aeap.2019.31.5.452 PMID: 31550196

34. National team Cambodia U, Optima Consortium for Decision Science,. Ending the AIDS epidemic in Cambodia. 2020. [http://optimamodel.com/pubs/Cambodia_HIV_2020.pdf].

35. Thin K, Prum V, Johns B. The cost of HIV services at health facilities in Cambodia. PLOS ONE. 2019; 14(5):e0216774. https://doi.org/10.1371/journal.pone.0216774 PMID: 31141514

36. Korenromp EL, Wi T, Resch S, Stover J, Broutet N. Costing of National STI Program Implementation for the Global STI Control Strategy for the Health Sector, 2016–2021. PLOS ONE. 2017; 12(1): e0170773. https://doi.org/10.1371/journal.pone.0170773 PMID: 28129372

37. World Health Organization. Global Price Reporting Mechanism Geneva: WHO; [http://apps.who.int/hiv/amds/price/hdd/].

38. World Health Organization. Country-specific inpatient and outpatient estimates in 2010 currency Geneva: WHO-CHOICE; [https://www.who.int/choice/cost-effectiveness/inputs/health_service/en/].

39. Sirgar AYM, Tromp N, Komarudin D, Wisaksana R, van Crevel R, van der Ven A, et al. Costs of HIV/AIDS treatment in Indonesia by time of treatment and stage of disease. BMC health services research. 2015; 15:440-. https://doi.org/10.1186/s12913-015-1098-3 PMID: 26424195

40. Government of Nepal MoH, National Centre for AIDS and STD Control Country Progress Report Nepal. 2017. [https://www.unaids.org/sites/default/files/country/documents/NPL_2018_countryreport.pdf].

41. Duong AT, Kato M, Bales S, Do NT, Minh Nguyen TT, Thanh Cao TT, et al. Costing analysis of national HIV treatment and care program in Vietnam. J Acquir Immune Defic Syndr. 2015; 14(8):921–8. https://doi.org/10.1097/QAI.0b013e3182a17d15 PMID: 23846564

42. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) Disability Weights. Seattle; 2017.

43. Wang H, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017; 390 (10100):1084–150.

44. Kazibwe J, Gheorghe A, Wilson D, Ruiz F, Chalkidou K, Chi YL. The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review. Value in Health. 2021.

45. Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, et al. Cost–effectiveness thresholds: pros and cons. B World Health Organ. 2016; 94(12):925. PMID: 27994285

46. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health. 2018; 3(6): e000964. https://doi.org/10.1136/bmjgh-2018-000964 PMID: 30483412

47. Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value in Health. 2016; 19(8):929–35. https://doi.org/10.1016/j.jval.2016.02.017 PMID: 27987642
48. The World Bank Group. GDP per capita (current US$) 2021 [https://data.worldbank.org/indicator/NY.GDP.PCAP.PD].

49. Cao W, Sun S, Peng L, Gu J, Hao C, Li J, et al. Low willingness to pay for pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in China. BMC Public Health. 2020; 20(1):337. https://doi.org/10.1186/s12889-020-08488-w PMID: 32178657

50. Draper BL, Fowkes FJI, Oo ZM, Thein ZW, Aung PP, Veronese V, et al. Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. J Int AIDS Soc. 2017; 20(1):21885. https://doi.org/10.7448/IAS.20.1.21885 PMID: 28741332

51. World Health Organization. Pre-exposure prophylaxis services in Thailand during COVID-19 2020 [https://www.who.int/news/item/26-11-2020-pre-exposure-prophylaxis-services-in-thailand-during-covid-19].

52. Son VH, Safarinejad A, Nga NT, Linh VM, Tu LTH, Manh PD, et al. Estimation of the Population Size of Men Who Have Sex With Men in Vietnam: Social App Multiplier Method. JMIR Public Health Surveill. 2019; 5(2):e12451. https://doi.org/10.2196/12451 PMID: 30994469

53. Baral S, Turner RM, Lyons CE, Howell S, Honermann B, Garner A, et al. Population Size Estimation of Gay and Bisexual Men and Other Men Who Have Sex With Men Using Social Media-Based Platforms. JMIR Public Health Surveill. 2018; 4(1):e15.

54. Phillips A, Bershtein A, Revill P, Banzi-Matharu L, Kripke K, Boily M-C, et al. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis (PrEP) in HIV epidemics in sub-Saharan Africa: a modelling study. The Lancet HIV. 2022. https://doi.org/10.1016/S2352-3018(22)00029-7 PMID: 35489378

55. Lau JYC, Hung C-T, Lee S-S. A review of HIV pre-exposure prophylaxis (PrEP) programmes by delivery models in the Asia-Pacific through the healthcare accessibility framework. Journal of the International AIDS Society. 2020; 23(7):e25531. https://doi.org/10.1002/jia2.25531 PMID: 32603517

56. Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, et al. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS Behav. 2017; 21(5):1325–35. https://doi.org/10.1007/s10461-016-1627-z PMID: 27900502

57. Janamnuaysook R, Green KE, Seekaew P, Ngoc Vu B, Van Ngo H, Anh Doan H, et al. Demedicalisation of HIV interventions to end HIV in the Asia-Pacific. Sex Health. 2021; 18(1):13–20. https://doi.org/10.1071/SH20172 PMID: 33632380

58. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. New England Journal of Medicine. 2021; 385(7):595–608. https://doi.org/10.1056/NEJMoa2101016 PMID: 34379922

59. ViiV Healthcare announces investigational injectable cabotegravir to be superior to oral standard of care for HIV prevention in women [press release]. 2020.

60. UNAIDS. Prevailing against pandemics: by putting people at the centre. 2020. [https://aidstargets2025.unaids.org/assets/images/p revailing-against-pandemics_en.pdf].